Published in Proc Natl Acad Sci U S A on August 22, 2008
Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev (2010) 5.83
Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth. Cancer Cell (2011) 4.43
The PSA(-/lo) prostate cancer cell population harbors self-renewing long-term tumor-propagating cells that resist castration. Cell Stem Cell (2012) 2.69
Androgen receptor promotes hepatitis B virus-induced hepatocarcinogenesis through modulation of hepatitis B virus RNA transcription. Sci Transl Med (2010) 1.84
Integrated expression profiling and ChIP-seq analyses of the growth inhibition response program of the androgen receptor. PLoS One (2009) 1.68
Targeting the stromal androgen receptor in primary prostate tumors at earlier stages. Proc Natl Acad Sci U S A (2008) 1.65
Role of autonomous androgen receptor signaling in prostate cancer initiation is dichotomous and depends on the oncogenic signal. Proc Natl Acad Sci U S A (2011) 1.53
Prostate-specific G-protein-coupled receptor collaborates with loss of PTEN to promote prostate cancer progression. Oncogene (2015) 1.49
Role of androgen receptor and associated lysine-demethylase coregulators, LSD1 and JMJD2A, in localized and advanced human bladder cancer. Mol Carcinog (2011) 1.37
Anti-androgen receptor ASC-J9 versus anti-androgens MDV3100 (Enzalutamide) or Casodex (Bicalutamide) leads to opposite effects on prostate cancer metastasis via differential modulation of macrophage infiltration and STAT3-CCL2 signaling. Cell Death Dis (2013) 1.36
Neuroendocrine differentiation in prostate cancer. Am J Transl Res (2009) 1.32
A new therapy paradigm for prostate cancer founded on clinical observations. Clin Cancer Res (2010) 1.32
ASC-J9 suppresses castration-resistant prostate cancer growth through degradation of full-length and splice variant androgen receptors. Neoplasia (2012) 1.28
Differential androgen deprivation therapies with anti-androgens casodex/bicalutamide or MDV3100/Enzalutamide versus anti-androgen receptor ASC-J9(R) Lead to promotion versus suppression of prostate cancer metastasis. J Biol Chem (2013) 1.23
Targeting the androgen receptor with siRNA promotes prostate cancer metastasis through enhanced macrophage recruitment via CCL2/CCR2-induced STAT3 activation. EMBO Mol Med (2013) 1.23
Hepatic androgen receptor suppresses hepatocellular carcinoma metastasis through modulation of cell migration and anoikis. Hepatology (2012) 1.21
The biology of progesterone receptor in the normal mammary gland and in breast cancer. Mol Cell Endocrinol (2011) 1.19
Androgen receptor splice variant AR3 promotes prostate cancer via modulating expression of autocrine/paracrine factors. J Biol Chem (2013) 1.18
Identification of betaArrestin2 as a corepressor of androgen receptor signaling in prostate cancer. Proc Natl Acad Sci U S A (2009) 1.17
Decreased tumorigenesis and mortality from bladder cancer in mice lacking urothelial androgen receptor. Am J Pathol (2013) 1.16
Combination therapy with a second-generation androgen receptor antagonist and a metastasis vaccine improves survival in a spontaneous prostate cancer model. Clin Cancer Res (2013) 1.15
Modeling a lethal prostate cancer variant with small-cell carcinoma features. Clin Cancer Res (2011) 1.15
Quantitative proteomic profiling of prostate cancer reveals a role for miR-128 in prostate cancer. Mol Cell Proteomics (2009) 1.13
Endothelial cells enhance prostate cancer metastasis via IL-6→androgen receptor→TGF-β→MMP-9 signals. Mol Cancer Ther (2013) 1.10
New therapeutic approach to suppress castration-resistant prostate cancer using ASC-J9 via targeting androgen receptor in selective prostate cells. Am J Pathol (2012) 1.08
Epidermal growth factor receptor expression escapes androgen regulation in prostate cancer: a potential molecular switch for tumour growth. Br J Cancer (2009) 1.08
Modeling prostate cancer in mice: something old, something new, something premalignant, something metastatic. Cancer Metastasis Rev (2013) 1.08
Prolonged androgen deprivation leads to downregulation of androgen receptor and prostate-specific membrane antigen in prostate cancer cells. Int J Oncol (2012) 1.06
Loss of stromal androgen receptor leads to suppressed prostate tumourigenesis via modulation of pro-inflammatory cytokines/chemokines. EMBO Mol Med (2012) 1.06
Androgen receptor (AR) positive vs negative roles in prostate cancer cell deaths including apoptosis, anoikis, entosis, necrosis and autophagic cell death. Cancer Treat Rev (2013) 1.05
Dysfunctional transforming growth factor-beta receptor II accelerates prostate tumorigenesis in the TRAMP mouse model. Cancer Res (2009) 1.04
Androgen hormone action in prostatic carcinogenesis: stromal androgen receptors mediate prostate cancer progression, malignant transformation and metastasis. Carcinogenesis (2012) 1.03
Persistent, biologically meaningful prostate cancer after 1 year of androgen ablation and docetaxel treatment. J Clin Oncol (2011) 1.01
Sustained proliferation in cancer: Mechanisms and novel therapeutic targets. Semin Cancer Biol (2015) 1.01
miR-200b inhibits prostate cancer EMT, growth and metastasis. PLoS One (2013) 1.00
Molecular processes leading to aberrant androgen receptor signaling and castration resistance in prostate cancer. Expert Rev Endocrinol Metab (2010) 1.00
Androgen deprivation therapy sensitizes prostate cancer cells to T-cell killing through androgen receptor dependent modulation of the apoptotic pathway. Oncotarget (2014) 1.00
Epithelial Hic-5/ARA55 expression contributes to prostate tumorigenesis and castrate responsiveness. Oncogene (2010) 0.97
Suppressed prostate epithelial development with impaired branching morphogenesis in mice lacking stromal fibromuscular androgen receptor. Mol Endocrinol (2011) 0.97
Wnt inhibitory factor 1 (Wif1) is regulated by androgens and enhances androgen-dependent prostate development. Endocrinology (2012) 0.96
Infiltrating mast cells enhance prostate cancer invasion via altering LncRNA-HOTAIR/PRC2-androgen receptor (AR)-MMP9 signals and increased stem/progenitor cell population. Oncotarget (2015) 0.96
Loss of epithelial oestrogen receptor α inhibits oestrogen-stimulated prostate proliferation and squamous metaplasia via in vivo tissue selective knockout models. J Pathol (2011) 0.94
Infiltrating T cells promote prostate cancer metastasis via modulation of FGF11→miRNA-541→androgen receptor (AR)→MMP9 signaling. Mol Oncol (2014) 0.93
From AR to c-Met: androgen deprivation leads to a signaling pathway switch in prostate cancer cells. Int J Oncol (2013) 0.92
The impact of point mutations in the human androgen receptor: classification of mutations on the basis of transcriptional activity. PLoS One (2012) 0.92
ARF represses androgen receptor transactivation in prostate cancer. Mol Endocrinol (2013) 0.92
A switch from CD44⁺ cell to EMT cell drives the metastasis of prostate cancer. Oncotarget (2015) 0.91
The diverse and contrasting effects of using human prostate cancer cell lines to study androgen receptor roles in prostate cancer. Asian J Androl (2008) 0.90
Identification of a cyclin D1 network in prostate cancer that antagonizes epithelial-mesenchymal restraint. Cancer Res (2013) 0.89
The tumor suppressor activity of the transmembrane protein with epidermal growth factor and two follistatin motifs 2 (TMEFF2) correlates with its ability to modulate sarcosine levels. J Biol Chem (2011) 0.89
Increased CK5/CK8-positive intermediate cells with stromal smooth muscle cell atrophy in the mice lacking prostate epithelial androgen receptor. PLoS One (2011) 0.88
The stroma-a key regulator in prostate function and malignancy. Cancers (Basel) (2012) 0.88
Understanding and targeting osteoclastic activity in prostate cancer bone metastases. Curr Mol Med (2013) 0.87
The pluripotency factor Nanog is directly upregulated by the androgen receptor in prostate cancer cells. Prostate (2014) 0.83
Minireview: Pathophysiological roles of the TR4 nuclear receptor: lessons learned from mice lacking TR4. Mol Endocrinol (2014) 0.83
Prolonged androgen deprivation leads to overexpression of calpain 2: implications for prostate cancer progression. Int J Oncol (2013) 0.83
Infiltrating bone marrow mesenchymal stem cells (BM-MSCs) increase prostate cancer cell invasion via altering the CCL5/HIF2α/androgen receptor signals. Oncotarget (2015) 0.82
Androgen receptor and immune inflammation in benign prostatic hyperplasia and prostate cancer. Clin Investig (Lond) (2014) 0.82
High SPDEF may identify patients who will have a prolonged response to androgen deprivation therapy. Prostate (2013) 0.82
Reduced prostate branching morphogenesis in stromal fibroblast, but not in epithelial, estrogen receptor α knockout mice. Asian J Androl (2012) 0.80
BM-MSCs promote prostate cancer progression via the conversion of normal fibroblasts to cancer-associated fibroblasts. Int J Oncol (2015) 0.80
MDC1 functionally identified as an androgen receptor co-activator participates in suppression of prostate cancer. Nucleic Acids Res (2015) 0.80
The activation of OR51E1 causes growth suppression of human prostate cancer cells. Oncotarget (2016) 0.79
Molecular markers in sex hormone pathway genes associated with the efficacy of androgen-deprivation therapy for prostate cancer. PLoS One (2013) 0.79
Acquired resistance to the second-generation androgen receptor antagonist enzalutamide in castration-resistant prostate cancer. Oncotarget (2016) 0.79
Differentially methylated genes and androgen receptor re-expression in small cell prostate carcinomas. Epigenetics (2016) 0.78
The miR-367-3p Increases Sorafenib Chemotherapy Efficacy to Suppress Hepatocellular Carcinoma Metastasis through Altering the Androgen Receptor Signals. EBioMedicine (2016) 0.78
Stromal androgen receptor regulates the composition of the microenvironment to influence prostate cancer outcome. Oncotarget (2015) 0.78
Inhibition of FOXC2 restores epithelial phenotype and drug sensitivity in prostate cancer cells with stem-cell properties. Oncogene (2016) 0.78
Quantification of mineralized bone response to prostate cancer by noninvasive in vivo microCT and non-destructive ex vivo microCT and DXA in a mouse model. PLoS One (2010) 0.78
Targeting inflammatory cytokines-androgen receptor (AR) signaling with ASC-J9(®) to better battle prostate cancer progression. Oncoimmunology (2013) 0.78
Supraphysiological androgen levels induce cellular senescence in human prostate cancer cells through the Src-Akt pathway. Mol Cancer (2014) 0.78
TR4 Nuclear Receptor Alters the Prostate Cancer CD133+ Stem/Progenitor Cell Invasion via Modulating the EZH2-Related Metastasis Gene Expression. Mol Cancer Ther (2015) 0.78
Prostate cancer stem cells: the role of androgen and estrogen receptors. Oncotarget (2015) 0.77
Quality of Life and Sexual Health in the Aging of PCa Survivors. Int J Endocrinol (2014) 0.77
The co-chaperone p23 promotes prostate cancer motility and metastasis. Mol Oncol (2014) 0.77
The importance of non-nuclear AR signaling in prostate cancer progression and therapeutic resistance. Cell Signal (2016) 0.77
Met in urological cancers. Cancers (Basel) (2014) 0.77
Local endocrine, paracrine and redox signaling networks impact estrogen and androgen crosstalk in the prostate cancer microenvironment. Steroids (2013) 0.77
The androgen receptor plays a suppressive role in epithelial- mesenchymal transition of human prostate cancer stem progenitor cells. BMC Biochem (2015) 0.76
Stromal factors involved in human prostate cancer development, progression and castration resistance. J Cancer Res Clin Oncol (2016) 0.75
ID4 promotes AR expression and blocks tumorigenicity of PC3 prostate cancer cells. Biochem Biophys Res Commun (2016) 0.75
Pathway bridge based multiobjective optimization approach for lurking pathway prediction. Biomed Res Int (2014) 0.75
KLF4 functions as an activator of the androgen receptor through reciprocal feedback. Oncogenesis (2016) 0.75
TCF7 is suppressed by the androgen receptor via microRNA-1-mediated downregulation and is involved in the development of resistance to androgen deprivation in prostate cancer. Prostate Cancer Prostatic Dis (2017) 0.75
AR Pathway Is Involved in the Regulation of CX43 in Prostate Cancer. Biomed Res Int (2015) 0.75
Androgen receptor differentially regulates the proliferation of prostatic epithelial cells in vitro and in vivo. Oncotarget (2016) 0.75
Neuroendocrine prostate cancer (NEPCa) increased the neighboring PCa chemoresistance via altering the PTHrP/p38/Hsp27/androgen receptor (AR)/p21 signals. Oncogene (2016) 0.75
Histone methyltransferase PRMT6 plays an oncogenic role of in prostate cancer. Oncotarget (2016) 0.75
Dissecting cell-type-specific roles of androgen receptor in prostate homeostasis and regeneration through lineage tracing. Nat Commun (2017) 0.75
Analysis of TMEFF2 allografts and transgenic mouse models reveals roles in prostate regeneration and cancer. Prostate (2015) 0.75
Stromal Androgen Receptor in Prostate Cancer Development and Progression. Cancers (Basel) (2017) 0.75
FGFR1 abrogates inhibitory effect of androgen receptor concurrent with induction of androgen-receptor variants in androgen receptor-negative prostate tumor epithelial cells. Prostate (2011) 0.75
Testosterone therapy in men with testosterone deficiency: Are we beyond the point of no return? Investig Clin Urol (2016) 0.75
PC-1 works in conjunction with E3 ligase CHIP to regulate androgen receptor stability and activity. Oncotarget (2016) 0.75
AR Signaling and the PI3K Pathway in Prostate Cancer. Cancers (Basel) (2017) 0.75
Use of real-time cellular analysis and Plackett-Burman design to develop the serum-free media for PC-3 prostate cancer cells. PLoS One (2017) 0.75
Genome-wide association study identifies novel breast cancer susceptibility loci. Nature (2007) 29.23
Androgen receptor in prostate cancer. Endocr Rev (2004) 7.92
Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene (2006) 5.86
Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation. Mech Dev (2001) 4.47
Metastatic prostate cancer in a transgenic mouse. Cancer Res (1996) 4.02
Molecular cloning of human and rat complementary DNA encoding androgen receptors. Science (1988) 3.96
CWR22: the first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar. Cancer Res (1996) 2.18
Is the Achilles' heel for prostate cancer therapy a gain of function in androgen receptor signaling? J Clin Endocrinol Metab (2003) 2.16
Generation of a transgenic mouse model with chondrocyte-specific and tamoxifen-inducible expression of Cre recombinase. Genesis (2007) 2.01
Increased prostate cell proliferation and loss of cell differentiation in mice lacking prostate epithelial androgen receptor. Proc Natl Acad Sci U S A (2007) 1.93
Establishment and characterization of osseous prostate cancer models: intra-tibial injection of human prostate cancer cells. Prostate (2002) 1.78
Roles for the stem cell associated intermediate filament Nestin in prostate cancer migration and metastasis. Cancer Res (2007) 1.76
Targeting the stromal androgen receptor in primary prostate tumors at earlier stages. Proc Natl Acad Sci U S A (2008) 1.65
High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate: cancer patients treated with radical prostatectomy. Am J Surg Pathol (2004) 1.61
Androgen-induced inhibition of cell proliferation in an androgen-insensitive prostate cancer cell line (PC-3) transfected with a human androgen receptor complementary DNA. Cancer Res (1993) 1.44
Abnormal mammary gland development and growth retardation in female mice and MCF7 breast cancer cells lacking androgen receptor. J Exp Med (2003) 1.42
A human prostatic stromal myofibroblast cell line WPMY-1: a model for stromal-epithelial interactions in prostatic neoplasia. Carcinogenesis (1999) 1.31
Identification of 3',5'-cyclic adenosine monophosphate response element and other cis-acting elements in the human androgen receptor gene promoter. Mol Endocrinol (1994) 1.30
Expression of basal cell keratins in human prostate cancer metastases and cell lines. J Pathol (2001) 1.26
Inherent increase of apoptosis in liver tumors: implications for carcinogenesis and tumor regression. Hepatology (1997) 1.17
Inhibition of the Akt, cyclooxygenase-2, and matrix metalloproteinase-9 pathways in combination with androgen deprivation therapy: potential therapeutic approaches for prostate cancer. Mol Carcinog (2005) 1.09
Apoptosis during breast carcinoma progression. Clin Cancer Res (1999) 1.08
Efficacy of ex vivo OPG gene therapy in preventing wear debris induced osteolysis. J Orthop Res (2002) 1.05
Imaging prostate cancer invasion with multi-nuclear magnetic resonance methods: the Metabolic Boyden Chamber. Neoplasia (2000) 1.01
Hic-5/ARA55, a LIM domain-containing nuclear receptor coactivator expressed in prostate stromal cells. Cancer Res (2006) 1.01
Interaction of Nkx3.1 and p27kip1 in prostate tumor initiation. Am J Pathol (2004) 0.92
The role of hormonal treatment in prostate cancer. Recent Results Cancer Res (2007) 0.88
Does androgen deprivation improve treatment outcomes in patients with low-risk and intermediate-risk prostate cancer? Nat Clin Pract Oncol (2005) 0.86
Androgen receptor in prostate cancer. Endocr Rev (2004) 7.92
Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol (2006) 4.64
Androgen receptor (AR) coregulators: an overview. Endocr Rev (2002) 4.01
Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment. J Immunol (2007) 3.81
Prostate cancer in the elderly: frequency of advanced disease at presentation and disease-specific mortality. Cancer (2011) 3.54
Phosphorylation-dependent ubiquitylation and degradation of androgen receptor by Akt require Mdm2 E3 ligase. EMBO J (2002) 3.27
Generation and characterization of androgen receptor knockout (ARKO) mice: an in vivo model for the study of androgen functions in selective tissues. Proc Natl Acad Sci U S A (2002) 3.08
Prostate-specific antigen screening for prostate cancer and the risk of overt metastatic disease at presentation: analysis of trends over time. Cancer (2012) 2.98
Growth retardation and abnormal maternal behavior in mice lacking testicular orphan nuclear receptor 4. Proc Natl Acad Sci U S A (2004) 2.78
Promotion of bladder cancer development and progression by androgen receptor signals. J Natl Cancer Inst (2007) 2.59
Role of the stromal microenvironment in carcinogenesis of the prostate. Int J Cancer (2003) 2.43
Infertility with defective spermatogenesis and hypotestosteronemia in male mice lacking the androgen receptor in Sertoli cells. Proc Natl Acad Sci U S A (2004) 2.41
Androgen receptor is a new potential therapeutic target for the treatment of hepatocellular carcinoma. Gastroenterology (2008) 2.36
Long-term outcome of patients with a negative work-up for asymptomatic microhematuria. Urology (2009) 2.18
The roles of androgen receptors and androgen-binding proteins in nongenomic androgen actions. Mol Endocrinol (2002) 2.12
Androgen deprivation therapy for prostate cancer: current status and future prospects. Prostate (2004) 1.96
Increased prostate cell proliferation and loss of cell differentiation in mice lacking prostate epithelial androgen receptor. Proc Natl Acad Sci U S A (2007) 1.93
Suppression versus induction of androgen receptor functions by the phosphatidylinositol 3-kinase/Akt pathway in prostate cancer LNCaP cells with different passage numbers. J Biol Chem (2003) 1.90
Acetylation of androgen receptor enhances coactivator binding and promotes prostate cancer cell growth. Mol Cell Biol (2003) 1.89
ASC-J9 ameliorates spinal and bulbar muscular atrophy phenotype via degradation of androgen receptor. Nat Med (2007) 1.87
Diagnosis, evaluation and follow-up of asymptomatic microhematuria (AMH) in adults: AUA guideline. J Urol (2012) 1.85
Androgen receptor promotes hepatitis B virus-induced hepatocarcinogenesis through modulation of hepatitis B virus RNA transcription. Sci Transl Med (2010) 1.84
The orphan nuclear receptor Nur77 regulates LKB1 localization and activates AMPK. Nat Chem Biol (2012) 1.75
Ubiquitination of a novel deubiquitinating enzyme requires direct binding to von Hippel-Lindau tumor suppressor protein. J Biol Chem (2001) 1.69
Androgen receptor in sertoli cell is essential for germ cell nursery and junctional complex formation in mouse testes. Endocrinology (2006) 1.69
Targeting the stromal androgen receptor in primary prostate tumors at earlier stages. Proc Natl Acad Sci U S A (2008) 1.65
Regulation of androgen receptor signaling by PTEN (phosphatase and tensin homolog deleted on chromosome 10) tumor suppressor through distinct mechanisms in prostate cancer cells. Mol Endocrinol (2004) 1.62
Monocyte/macrophage androgen receptor suppresses cutaneous wound healing in mice by enhancing local TNF-alpha expression. J Clin Invest (2009) 1.62
IL-6 expression regulates tumorigenicity and correlates with prognosis in bladder cancer. PLoS One (2013) 1.62
Neoadjuvant gemcitabine and cisplatin chemotherapy for locally advanced urothelial cancer of the bladder. Cancer (2011) 1.62
Activation of Ras/Erk pathway by a novel MET-interacting protein RanBPM. J Biol Chem (2002) 1.62
Bisphenol a and reproductive health: update of experimental and human evidence, 2007-2013. Environ Health Perspect (2014) 1.61
VHL protein-interacting deubiquitinating enzyme 2 deubiquitinates and stabilizes HIF-1alpha. EMBO Rep (2005) 1.57
Antitumor agents. 217. Curcumin analogues as novel androgen receptor antagonists with potential as anti-prostate cancer agents. J Med Chem (2002) 1.57
Identification of a deubiquitinating enzyme subfamily as substrates of the von Hippel-Lindau tumor suppressor. Biochem Biophys Res Commun (2002) 1.56
Androgen receptor roles in spermatogenesis and fertility: lessons from testicular cell-specific androgen receptor knockout mice. Endocr Rev (2009) 1.55
A randomized controlled trial of intravesical bacillus calmette-guerin for treatment refractory interstitial cystitis. J Urol (2005) 1.54
Finasteride treatment alters tissue specific androgen receptor expression in prostate tissues. Prostate (2014) 1.50
Reduced bladder cancer recurrence rate with cardioprotective aspirin after intravesical bacille Calmette-Guérin. BJU Int (2008) 1.48
Androgen receptor acetylation governs trans activation and MEKK1-induced apoptosis without affecting in vitro sumoylation and trans-repression function. Mol Cell Biol (2002) 1.48
Adjuvant concurrent chemoradiotherapy with intensity-modulated pelvic radiotherapy after surgery for high-risk, early stage cervical cancer patients. Cancer J (2008) 1.47
Expression of androgen and oestrogen receptors and its prognostic significance in urothelial neoplasm of the urinary bladder. BJU Int (2012) 1.46
Induction of androgen receptor expression by phosphatidylinositol 3-kinase/Akt downstream substrate, FOXO3a, and their roles in apoptosis of LNCaP prostate cancer cells. J Biol Chem (2005) 1.46
Complications associated with extraperitoneal robot-assisted radical prostatectomy using the standardized Martin classification. Urology (2013) 1.44
Androgens and estrogens in benign prostatic hyperplasia: past, present and future. Differentiation (2011) 1.42
Abnormal mammary gland development and growth retardation in female mice and MCF7 breast cancer cells lacking androgen receptor. J Exp Med (2003) 1.42
Gender, racial and age differences in bladder cancer incidence and mortality. Urol Oncol (2004) 1.41
Identifying additional lymph nodes in radical cystectomy lymphadenectomy specimens. Mod Pathol (2011) 1.41
Microscopic invasion of perivesical fat by urothelial carcinoma: implications for prognosis and pathology practice. Urology (2010) 1.41
Bladder tumor markers. J Urol (2006) 1.40
Recent advances in the TR2 and TR4 orphan receptors of the nuclear receptor superfamily. J Steroid Biochem Mol Biol (2002) 1.39
Subfertility and defective folliculogenesis in female mice lacking androgen receptor. Proc Natl Acad Sci U S A (2004) 1.39
Loss of TR4 orphan nuclear receptor reduces phosphoenolpyruvate carboxykinase-mediated gluconeogenesis. Diabetes (2007) 1.39
Interleukin-6 differentially regulates androgen receptor transactivation via PI3K-Akt, STAT3, and MAPK, three distinct signal pathways in prostate cancer cells. Biochem Biophys Res Commun (2003) 1.36
Near infrared fluorescence imaging with robotic assisted laparoscopic partial nephrectomy: initial clinical experience for renal cortical tumors. J Urol (2011) 1.35
NF-kappaB regulates androgen receptor expression and prostate cancer growth. Am J Pathol (2009) 1.35
Insulin and leptin resistance with hyperleptinemia in mice lacking androgen receptor. Diabetes (2005) 1.33
TR4 nuclear receptor functions as a fatty acid sensor to modulate CD36 expression and foam cell formation. Proc Natl Acad Sci U S A (2009) 1.33
Increased hepatic steatosis and insulin resistance in mice lacking hepatic androgen receptor. Hepatology (2008) 1.32
Deficits in motor coordination with aberrant cerebellar development in mice lacking testicular orphan nuclear receptor 4. Mol Cell Biol (2005) 1.31
Quantitative characterization of viscoelastic properties of human prostate correlated with histology. Ultrasound Med Biol (2008) 1.30
Liquiritigenin is a plant-derived highly selective estrogen receptor beta agonist. Mol Cell Endocrinol (2007) 1.30
ASC-J9 suppresses castration-resistant prostate cancer growth through degradation of full-length and splice variant androgen receptors. Neoplasia (2012) 1.28
Targeted inactivation of testicular nuclear orphan receptor 4 delays and disrupts late meiotic prophase and subsequent meiotic divisions of spermatogenesis. Mol Cell Biol (2004) 1.27
Androgen receptor corepressors: an overview. Prostate (2005) 1.25
Differential effects of spermatogenesis and fertility in mice lacking androgen receptor in individual testis cells. Proc Natl Acad Sci U S A (2006) 1.25